LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

Search

Rhythm Pharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

95.31 -0.6

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

94.01

Max

96.47

Schlüsselkennzahlen

By Trading Economics

Einkommen

2.9M

-47M

Verkäufe

16M

49M

Gewinnspanne

-96.144

Angestellte

283

EBITDA

6.9M

-40M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+16.71% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

4. Nov. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

672M

6.6B

Vorheriger Eröffnungskurs

95.91

Vorheriger Schlusskurs

95.31

Nachrichtenstimmung

By Acuity

20%

80%

43 / 371 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bearish Evidence

Rhythm Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

16. Sept. 2025, 17:03 UTC

Wichtige Markttreiber

BrainsWay Shares Rise on FDA Clearance of Major Depressive Disorder Treatment

16. Sept. 2025, 16:49 UTC

Wichtige Markttreiber
Akquisitionen, Fusionen, Übernahmen

GD Culture Shares Drop After Deal for Pallas Capital

16. Sept. 2025, 16:11 UTC

Wichtige Markttreiber

Corbus Shares Rise on FDA Fast-Track Designation for Cancer Drug

16. Sept. 2025, 23:40 UTC

Market Talk

Nikkei May Decline as Yen Strengthens -- Market Talk

16. Sept. 2025, 23:34 UTC

Market Talk

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

16. Sept. 2025, 23:20 UTC

Market Talk

Restaurant Brands NZ Can Outperform When Cycle Turns -- Market Talk

16. Sept. 2025, 21:10 UTC

Akquisitionen, Fusionen, Übernahmen

U.S. Investors, Trump Close In on TikTok Deal With China -- WSJ

16. Sept. 2025, 20:51 UTC

Market Talk

U.S. Home Sales, New Home Listings Fall in August -- Market Talk

16. Sept. 2025, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

16. Sept. 2025, 20:50 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Basic Materials Roundup: Market Talk

16. Sept. 2025, 20:25 UTC

Ergebnisse

The AI Trade Has Stocks Near Highs Again. Some Tech Names Remain on the Sidelines -- Barrons.com

16. Sept. 2025, 20:24 UTC

Ergebnisse

These Stocks Moved the Most Today: Oracle, Tesla, Alphabet, Dave & Buster's, Chipotle, and More -- Barrons.com

16. Sept. 2025, 19:19 UTC

Market Talk

U.S. Natural Gas Futures Extend Winning Streak -- Market Talk

16. Sept. 2025, 18:52 UTC

Market Talk

Oil Futures Advance on Russia Concerns, Weak Dollar -- Market Talk

16. Sept. 2025, 18:44 UTC

Market Talk

Global Equities Roundup: Market Talk

16. Sept. 2025, 18:44 UTC

Market Talk

EssilorLuxottica Well-Positioned in Growing Smart-Glasses Market -- Market Talk

16. Sept. 2025, 18:40 UTC

Akquisitionen, Fusionen, Übernahmen

Details Emerge on U.S.-China TikTok Deal -- WSJ

16. Sept. 2025, 18:38 UTC

Market Talk

Meta Seen With Long-Term Opportunity to Lead in Smart Glasses -- Market Talk

16. Sept. 2025, 18:19 UTC

Market Talk

Gold Settles at New High Ahead of Fed Decision -- Market Talk

16. Sept. 2025, 18:01 UTC

Market Talk

U.S. Dollar Weakness Supports Oil's Gains -- Market Talk

16. Sept. 2025, 17:34 UTC

Market Talk

Any Question the Bank of Canada Will Cut Now Look to Have Vanished -- Market Talk

16. Sept. 2025, 16:53 UTC

Ergebnisse

Software Companies Are Fighting Back With AI. The Stocks Are Still Hurting. -- Barrons.com

16. Sept. 2025, 16:20 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Basic Materials Roundup: Market Talk

16. Sept. 2025, 16:15 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Global Commodities Roundup: Market Talk

16. Sept. 2025, 16:09 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Global Energy Roundup: Market Talk

16. Sept. 2025, 16:09 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Canada Industry Minister to Meet Mining CEOs on Merger -- Market Talk

16. Sept. 2025, 15:35 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16. Sept. 2025, 15:35 UTC

Market Talk

Gold Soars Past $3,700 Ahead of Fed Decision -- Market Talk

16. Sept. 2025, 15:22 UTC

Market Talk

More Investors Think Dollar is Overvalued in Latest BofA Survey -- Market Talk

16. Sept. 2025, 15:21 UTC

Market Talk

Sterling Considered Most Overvalued in Nearly 10 Years -- Market Talk

Peer-Vergleich

Kursveränderung

Rhythm Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

16.71% Vorteil

12-Monats-Prognose

Durchschnitt 112.08 USD  16.71%

Hoch 135 USD

Tief 95 USD

Basierend auf 13 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Rhythm Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

13 ratings

13

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

60 / 65.58Unterstützung & Widerstand

Kurzfristig

Strong Bearish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Bullish Evidence

Stimmung

By Acuity

43 / 371 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
help-icon Live chat